…
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
XWELL Inc. is listed on NASDAQ under ticker XWEL; publicly available disclosures about its business operations and segments are limited. Because detailed information is not accessible, major long-term growth drivers cannot be confirmed; investors may find the company's listing and any forthcoming filings or corporate updates of interest for assessing its strategy and prospects.
Key risks include the lack of publicly available operational and financial disclosure, potential early-stage or thinly traded status, and attendant liquidity, governance and execution uncertainties; investors should monitor regulatory filings and management communications.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -32.57M | 3.03M | -92.22M | -20.68M | -35.91M |
| Minority interest | -0.21M | 0.46M | 1.74M | -0.69M | -0.46M |
| Net income | -32.63M | 3.35M | -92.23M | -20.53M | -37.20M |
| Selling general administrative | 31.17M | 24.20M | 15.94M | 14.32M | 16.24M |
| Gross profit | 12.05M | 32.43M | -3.60M | 10.66M | 10.64M |
| Reconciled depreciation | 7.27M | 4.92M | 7.22M | 6.12M | 9.50M |
| Ebit | -24.55M | 5.87M | -40.10M | -9.78M | -14.60M |
| Ebitda | -9.38M | 10.78M | -16.66M | -5.56M | -5.10M |
| Depreciation and amortization | 15.17M | 4.92M | 23.44M | 4.22M | 9.50M |
| Operating income | -24.55M | 5.87M | -40.10M | -9.78M | -34.73M |
| Other operating expenses | 80.49M | 68.70M | 33.13M | 58.30M | 65.19M |
| Interest expense | 16.13M | 2.38M | 1.83M | 2.90M | 1.83M |
| Tax provision | 0.06M | 0.06M | 0.01M | -0.15M | -0.28M |
| Interest income | - | 0.04M | - | - | - |
| Net interest income | -0.08M | -0.10M | -1.83M | -2.90M | -1.83M |
| Income tax expense | 0.06M | 0.14M | 0.01M | -0.15M | -0.28M |
| Total revenue | 55.94M | 73.73M | 8.38M | 48.52M | 50.09M |
| Total operating expenses | 36.60M | 27.40M | 21.15M | 20.44M | 25.74M |
| Cost of revenue | 43.89M | 41.30M | 11.98M | 37.85M | 39.45M |
| Total other income expense net | -8.02M | -2.83M | -52.12M | -10.89M | -18.99M |
| Discontinued operations | - | - | - | - | -1.11M |
| Net income from continuing ops | -32.63M | 2.89M | -92.23M | -20.53M | -35.63M |
| Net income applicable to common shares | -32.84M | 3.35M | -91.43M | -21.22M | -37.20M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 38.99M | 70.43M | 127.27M | 103.13M | 28.72M |
| Intangible assets | 1.35M | 4.01M | 3.73M | 0.87M | 6.78M |
| Other current assets | 0.95M | 0.05M | 1.09M | 0.19M | 0.12M |
| Total liab | 18.02M | 22.48M | 27.33M | 22.76M | 31.26M |
| Total stockholder equity | 13.00M | 39.93M | 92.73M | 77.81M | -6.24M |
| Other current liab | 4.97M | 5.72M | 6.99M | 4.06M | 1.81M |
| Common stock | 0.04M | 0.83M | 1.01M | 0.94M | 0.49M |
| Capital stock | 0.04M | 0.83M | 1.01M | 0.94M | 0.50M |
| Retained earnings | -455.85M | -428.11M | -395.27M | -398.62M | -308.14M |
| Other liab | - | - | - | - | 3.45M |
| Good will | 1.37M | 4.02M | - | - | - |
| Other assets | - | - | 2.84M | -0.00M | 1.21M |
| Cash | 8.44M | 19.04M | 105.51M | 89.80M | 2.18M |
| Total current liabilities | 9.33M | 10.96M | 19.83M | 13.48M | 16.22M |
| Current deferred revenue | 0.86M | 0.34M | 0.55M | 0.89M | 3.68M |
| Net debt | 2.66M | -4.93M | -91.68M | -74.42M | 13.07M |
| Short term debt | 2.40M | 2.59M | 6.32M | 6.09M | 3.67M |
| Short long term debt | - | - | 3.58M | 3.30M | - |
| Short long term debt total | 11.09M | 14.11M | 13.82M | 15.38M | 15.26M |
| Other stockholder equity | 470.74M | 467.74M | 487.31M | 475.71M | 301.68M |
| Property plant equipment | - | 11.94M | 10.99M | 7.20M | 16.32M |
| Total current assets | 26.57M | 47.33M | 108.98M | 91.78M | 3.93M |
| Long term investments | 0.05M | 0.10M | 0.72M | 1.77M | 0.48M |
| Net tangible assets | - | 31.89M | 89.00M | 76.94M | -13.03M |
| Short term investments | 14.61M | 23.15M | - | - | - |
| Net receivables | 1.67M | 2.86M | 0.61M | 1.14M | 0.98M |
| Long term debt | - | - | - | 2.35M | 5.76M |
| Inventory | 0.90M | 1.16M | 1.76M | 0.66M | 0.65M |
| Accounts payable | 1.10M | 2.31M | 5.97M | 2.44M | 7.07M |
| Accumulated other comprehensive income | -1.92M | -0.53M | -0.31M | -0.22M | -0.28M |
| Non currrent assets other | 1.79M | 3.02M | 3.56M | 0.79M | 0.45M |
| Non current assets total | 12.43M | 23.09M | 18.29M | 11.36M | 24.79M |
| Capital lease obligations | 11.09M | 14.11M | 10.24M | 9.73M | 9.49M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -34.84M | -5.16M | -4.35M | -2.27M | 0.20M |
| Change to liabilities | -4.18M | 6.32M | -5.17M | 3.76M | -0.60M |
| Total cashflows from investing activities | -34.84M | -5.16M | -4.35M | -2.27M | -1.87M |
| Net borrowings | -3.58M | -2.07M | 6.24M | 2.87M | 4.35M |
| Total cash from financing activities | -27.38M | 6.35M | 117.22M | 1.17M | 5.64M |
| Change to operating activities | -4.51M | -2.46M | -3.19M | -0.67M | -1.89M |
| Net income | -32.63M | 2.89M | -92.23M | -20.53M | -35.63M |
| Change in cash | -86.47M | 15.76M | 87.87M | -1.25M | -2.96M |
| Begin period cash flow | 106.26M | 90.50M | 2.63M | 3.89M | 6.86M |
| End period cash flow | 19.79M | 106.26M | 90.50M | 2.63M | 3.89M |
| Total cash from operating activities | -24.19M | 15.64M | -25.01M | -0.11M | -6.57M |
| Issuance of capital stock | 0.00M | 17.09M | 110.62M | 0.00M | 3.00M |
| Depreciation | 7.27M | 4.92M | 7.22M | 6.12M | 9.50M |
| Dividends paid | - | -0.01M | - | - | - |
| Change to inventory | 0.59M | -1.11M | -0.01M | 0.14M | 0.38M |
| Change to account receivables | -1.83M | -0.48M | -1.12M | -1.12M | -1.83M |
| Sale purchase of stock | -23.86M | -7.83M | - | - | - |
| Other cashflows from financing activities | -0.03M | -0.83M | 6.61M | 1.29M | 5.64M |
| Change to netincome | 11.31M | 4.66M | 65.36M | 8.46M | 24.37M |
| Capital expenditures | 6.84M | 8.67M | 4.35M | 2.27M | 3.12M |
| Change in working capital | -9.94M | 2.71M | -8.36M | 4.54M | -2.12M |
| Stock based compensation | 3.77M | 2.86M | 1.33M | 0.34M | 0.92M |
| Other non cash items | 7.33M | 0.38M | 1.63M | 4.81M | 1.54M |
| Free cash flow | -31.02M | 6.97M | -29.36M | -2.39M | -9.68M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XWEL XWELL Inc. |
-0.03 5.77% |
0.41 | - | - | 0.20 | 0.31 | 0.07 | 0.49 |
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott R. Milford | Pres, CEO & Director | 1964 |
| Mr. Omar A. Haynes | Interim Chief Financial Officer | 1982 |
| Mr. David Kohel | Chief Technology Officer | NA |
| Ms. Cara Soffer | Sr. VP & Gen. Counsel | NA |
| Pablo Henderson | Chief Marketing Officer | NA |
| Mr. Ezra Ernst | Chief Exec. Officer of XpresTest, Inc. | NA |
| Mr. Scott R. Milford | President, CEO & Director | 1964 |
| Mr. Ezra T. Ernst | Executive Vice President | 1969 |
| Mr. Omar A. Haynes | VP of Treasury & Finance | 1983 |
| Ms. Suzanne Scrabis | Chief Financial Officer | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.